News archive — Thuja

Focus & approach

Team & Partners

Team Investment Management

News & Events

Impact & ESG

impact Committee

News archive

Featured

Meet Eline van Beest, Operational Partner at Thuja

Meet Eline van Beest, Operational Partner at Thuja

2023 Impact & ESG picture.png

Thuja's 2023 Impact & ESG Annual Report

Synerkine Pharma receives European Orphan Drug Designation for SK-01 to treat Complex Regional Pain Syndrome

Synerkine Pharma receives European Orphan Drug Designation for SK-01 to treat Complex Regional Pain Syndrome

We are delighted to share that Thuja led the extension of Tacalyx’s seed financing!

We are delighted to share that Thuja led the extension of Tacalyx’s seed financing!

FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer

FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer

Meet Tyler Hayes, Principal at Thuja

Meet Tyler Hayes, Principal at Thuja

FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine

FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine

Thuja promotes Eleanor Price to Associate

Thuja promotes Eleanor Price to Associate

Meet Aartie Nanda, office & communication manager at Thuja

Meet Aartie Nanda, office & communication manager at Thuja

Thuja Capital co-leads a €12M Seed investment in Artica Therapeutics.

Thuja Capital co-leads a €12M Seed investment in Artica Therapeutics.

Synerkine Pharma secures EUR 12.1 million to accelerate novel pain therapeutics towards clinical proof-of-concept

Synerkine Pharma secures EUR 12.1 million to accelerate novel pain therapeutics towards clinical proof-of-concept

Thuja invests in Gradient Denervation Technologies